These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
749 related articles for article (PubMed ID: 26942591)
1. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection. Kapoor P; Paludo J; Ansell SM Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591 [TBL] [Abstract][Full Text] [Related]
2. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease. Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994 [TBL] [Abstract][Full Text] [Related]
3. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664 [TBL] [Abstract][Full Text] [Related]
4. Significances of MYD88 Meng Q; Cao XX; Li J Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):578-582. PubMed ID: 28877839 [TBL] [Abstract][Full Text] [Related]
5. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114 [TBL] [Abstract][Full Text] [Related]
6. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review. Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930 [No Abstract] [Full Text] [Related]
7. Current approach to Waldenström Macroglobulinemia. Ravi G; Kapoor P Cancer Treat Res Commun; 2022; 31():100527. PubMed ID: 35149375 [TBL] [Abstract][Full Text] [Related]
8. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Treon SP; Cao Y; Xu L; Yang G; Liu X; Hunter ZR Blood; 2014 May; 123(18):2791-6. PubMed ID: 24553177 [TBL] [Abstract][Full Text] [Related]